Diagnosis and classification of pulmonary arterial hypertension;Diagnostic et classification des hypertensions artérielles pulmonaires

Presse Medicale

Volumn 34, Issue 19 II, 2005, Pages 1435-1444

  Provencher, Steeve ^a,b   Martel, S ^a   Jais, X ^b   Sitbon, O ^b   Humbert, M ^b   Simonneau, G ^b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOREX; AMPHETAMINE DERIVATIVE; ANOREXIGENIC AGENT; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; COCAINE; DEXFENFLURAMINE; ESTROGEN; FENFLURAMINE; FUMARIC ACID; METHAMPHETAMINE; TRYPTOPHAN;

ARTERY RESISTANCE; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; HEART DISEASE; HEART FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LUNG BIOPSY; METHODOLOGY; PHYSICAL EXAMINATION; PORTAL HYPERTENSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR;

EID: 27744546316     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(05)84205-8     Document Type: Review

References (76)

1. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, Gaine S. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 40S-47S.
2. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5S-12S.
3. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655-65.
4. Humbert M, Chaouat A, Bertocchi M. ItinerAIR-HTAP: a French national prospective registry of pulmonary arterial hypertension (abstract). Am J Resp Crit Care Med 2004; 169: A56.
5. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-36.
6. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA 3rd, Loyd JE et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000; 26: 81-4.
7. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67: 737-44.
8. Sztrymf B, Francoual J, Sitbon O, Labrune P, Jambou M, Pous C et al. Clinical, haemodynamic and genetic features of familial pulmonary arterial hypertension. Rev Mal Respir 2004; 21: 909-15.
9. Humbert M, Deng Z, Simonneau G, Barst RJ, Sitbon O, Wolf M et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J 2002; 20: 518-23.
10. Roberts KE, McElroy JJ, Wong WP, Yen E, Widlitz A, Barst RJ et al. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J 2004; 24: 371-4.
11. Kay JM, Smith P, Heath D. Aminorex and the pulmonary circulation. Thorax 1971; 26: 262-70.
12. Gurtner HP. Aminorex and pulmonary hypertension. A review. Cor Vasa 1985; 27: 160-71.
13. Follath F, Burrart F, Schweizer W. Drug-induced pulmonary hypertension? Br Med J 1971; 1: 265-6.
14. Loogen F, Worth H, Schwan G, Goeckenjan G, Losse B, Horstkotte D. Long-term follow-up of pulmonary hypertension in patients with and without anorectic drug intake. Cor Vasa 1985; 27: 111-24.
15. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335: 609-16.
16. Rich S, Rubin L, Walker AM, Schneeweiss S, Abenhaim L. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest 2000; 117: 870-4.
17. Martin F, Artigas F. Simultaneaous effects of p-chloramphetamine, d-fenfluramine, and reserpine on free blood and stored 5-HT in brain and blood. J Neurochem 1992; 59: 1138-44.
18. Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62: 1088-93.
19. Pan TL, Thumboo J, Boey ML. Primary and secondary pulmonary hypertension in systemic lupus erythematosus. Lupus 2000; 9: 338-42.
20. Sanchez O, Garcia G, Hamid A, Nunes H, Ioos V, Andriamihoatra TH et al. Les hypertensions pulmonaires compliquant des maladies systémiques en dehors des connectivites. Presse Med 2003; 32: 800-3.
21. Fagan KA, Badesch DB. Pulmonary hypertension associated with connective tissue disease. Prog Cardiovasc Dis 2002; 45: 225-34.
22. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123: 344-50.
23. McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126: 14S-34.
24. Hachulla E, Gressin V, Guillevin L, de Groote P, Cabane J, Carpentier P et al. Pulmonary arterial hypertension in systemic sclerosis: definition of a screening algorithm for early detection (the ItinerAIR-Sclerodermie Study). Rev Med Interne 2004; 25: 340-7.
25. Daliento L, Somerville J, Presbitero P, Menti L, Brach-Prever S, Rizzoli G, Stone S. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J 1998; 19: 1845-55.
26. Hoffman JI, Rudolph AM. The natural history of ventricular septal defects in infancy. Am J Cardiol 1965; 16: 634-53.
27. Vogel M, Berger F, Kramer A, Alexi-Meshkishvili V, Lange PE. Incidence of secondary pulmonary hypertension in adults with atrial septal or sinus venosus defects. Heart 1999; 82: 30-3.
28. Kidd L, Driscoll DJ, Gersony WM, Hayes CJ, Keane JF, O'Fallon WM et al. Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. Circulation 1993; 87: 138-51.
29. Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur Heart J 2004; 25: 2243-78.
30. Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996; 1: 100-5.
31. Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J 2004; 24: 861-80.
32. Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991; 100: 520-8.
33. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004; 363: 1461-8.
34. Lebrec D, Capron JP, Dhumeaux D, Benhamou JP. Pulmonary hypertension complicating portal hypertension. Am Rev Respir Dis 1979; 120: 849-56.
35. Herve P, Lebrec D, Brenot F, Simonneau G, Humbert M, Sitbon O, Duroux P. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998; 11: 1153-66.
36. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000; 6: 443-50.
37. Humbert M, Nunes H, Sitbon O, Parent F, Herve P, Simonneau G. Risk factors for pulmonary arterial hypertension. Clin Chest Med 2001; 22: 459-75.
38. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-Related pulmonary hypertension: analytic review of 131 cases. Chest 2000; 118: 1133-41.
39. Opravil M, Pechere M, Speich R, Joller-Jemelka HI, Jenni R, Russi EW et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997; 155: 990-5.
40. Humbert M, Monti G, Fartoukh M, Magnan A, Brenot F, Rain B et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998; 11: 554-9.
41. Mette SA, Palevsky HI, Pietra GG, Williams TM, Bruder E, Prestipino AJ et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am Rev Respir Dis 1992; 145: 1196-200.
42. Petitpretz P, Brenot F, Azarian R, Parent F, Rain B, Herve P, Simonneau G. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation 1994; 89: 2722-7.
43. Nunes H, Humbert M, Sitbon O, Morse JH, Deng Z, Knowles JA et al. Prognostic Factors for Survival in Human Immunodeficiency Virus-associated Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2003; 167: 1433-9.
44. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004; 43: 25S-32S.
45. Humbert M, Maitre S, Capron F, Rain B, Musset D, Simonneau G. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. Am J Respir Crit Care Med 1998; 157: 1681-5.
46. Holcomb BW Jr, Loyd JE, Ely EW, Johnson J, Robbins IM. Pulmonary venoocclusive disease: a case series and new observations. Chest 2000; 118: 1671-9.
47. Resten A, Maitre S, Humbert M, Rabiller A, Sitbon O, Capron F et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. AJR Am J Roentgenol 2004; 183: 65-70.
48. Dufour B, Maitre S, Humbert M, Capron F, Simonneau G, Musset D. High-resolution CT of the chest in four patients with pulmonary capillary hemangiomatosis or pulmonary venoocclusive disease. AJR Am J Roentgenol 1998; 171: 1321-4.
49. Swensen SJ, Tashjian JH, Myers JL, Engeler CE, Patz EF, Edwards WD, Douglas WW. Pulmonary venoocclusive disease: CT findings in eight patients. AJR Am J Roentgenol 1996; 167: 937-40.
50. Rabiller A, Humbert M, Sitbon M. Bronchoalveolar lavage as a diagnostic tool in pulmonary hypertension: occult alveolar hemorrhage is a common feature of pulmonary venoocclusive disease. Am J Resp Crit Care Med 2003; 167: A276.
51. Scorza R, Caronni M, Bazzi S, Nador F, Beretta L, Antonioli R et al. Postmenopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis. Ann N Y Acad Sci 2002; 966: 238-46.
52. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48: 516-22.
53. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107: 216-23.
54. Ahearn GS, Tapson VF, Rebeiz A, Greenfield JC Jr. Electrocardiography to define clinical status in primary pulmonary hypertension and pulmonary arterial hypertension secondary to collagen vascular disease. Chest 2002; 122: 524-7.
55. Borgeson DD, Seward JB, Miller FA Jr, Oh JK, Tajik AJ. Frequency of Doppler measurable pulmonary artery pressures. J Am Soc Echocardiogr 1996; 9: 832-7.
56. Grunig E, Janssen B, Mereles D, Barth U, Borst MM, Vogt IR et al. Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene. Circulation 2000; 102: 1145-50.
57. Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, Bois RM. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 1997; 36: 239-43.
58. Chemla D, Castelain V, Herve P, Lecarpentier Y, Brimioulle S. Haemodynamic evaluation of pulmonary hypertension. Eur Respir J 2002; 20: 1314-31.
59. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S et al. Long-term response to calcium-channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111 (23): 3105-11.
60. Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001; 345: 1465-72.
61. Rich S, Kieras K, Hart K, Groves BM, Stobo JD, Brundage BH. Antinuclear antibodies in primary pulmonary hypertension. J Am Coll Cardiol 1986; 8: 1307-11.
62. Albrecht T, Blomley MJ, Cosgrove DO, Taylor-Robinson SD, Jayaram V, Eckersley R et al. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet 1999; 353: 1579-83.
63. Naeije R. Hepatopulmonary syndrome and portopulmonary hypertension. Swiss Med Wkly 2003; 133: 163-9.
64. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective study. Ann Intern Med 1991; 115: 343-9.
65. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161: 487-92.
66. Paciocco G, Martinez FJ, Bossone E, Pielsticker E, Gillespie B, Rubenfire M. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J 2001; 17: 647-52.
67. Rhodes J, Barst RJ, Garofano RP, Thoele DG, Gersony WM. Hemodynamic correlates of exercise function in patients with primary pulmonary hypertension. J Am Coll Cardiol 1991; 18: 1738-44.
68. Wensel R, Opitz CF, Anker SD, Winkler J, Hoffken G, Kleber FX et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 2002; 106: 319-24.
69. Eysmann SB, Palevsky HI, Reichek N, Hackney K, Douglas PS. Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension. Circulation 1989; 80: 353-60.
70. Raymond RJ, Hinderliter AL, Willis PW, Ralph D, Caldwell EJ, Williams W et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002; 39: 1214-19.
71. Yeo TC, Dujardin KS, Tei C, Mahoney DW, McGoon MD, Seward JB. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 1998; 81: 1157-61.
72. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. J Cardiol 2001; 37: 110-1.
73. Torbicki A, Kurzyna M, Kuca P, Fijalkowska A, Sikora J, Florczyk M et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003; 108: 844-8.
74. Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schultheiss HP, Hoeffken G. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001; 120: 1562-9.
75. Nagaya N, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Nakanishi N et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 1999; 160: 487-92.
76. Nootens M, Kaufmann E, Rector T, Toher C, Judd D, Francis GS, Rich S. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 1995; 26: 1581-5.